Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
:GSK
GSK Stock Chart & Stats
$48.81
-$0.16(-0.33%)
At close: 4:00 PM EST
$48.81
-$0.16(-0.33%)
Day’s Range― - ―
52-Week Range$31.72 - $49.31
Previous CloseN/A
Volume2.85M
Average Volume (3M)4.15M
Market Cap
$98.47B
Enterprise Value$107.43B
Total Cash (Recent Filing)$4.45B
Total Debt (Recent Filing)$23.90B
Price to Earnings (P/E)13.7
Beta0.29
Next Earnings
Feb 04, 2026EPS Estimate
0.63Next Dividend Ex-DateN/A
Dividend Yield3.42%
Share Statistics
EPS (TTM)1.46
Shares Outstanding2,038,406,300
10 Day Avg. Volume3,587,546
30 Day Avg. Volume4,149,989
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)4.03
Price to Sales (P/S)1.76
P/FCF Ratio15.42
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue3.34
Enterprise Value/Gross Profit4.62
Enterprise Value/Ebitda9.94
Forecast
1Y Price Target
$43.00Price Target Upside-11.90% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of efimosfermin is sound given that it expands GSK's hepatology portfolio, provides optionality to related diseases, and fits within GSK's BD strategy.
Pipeline DevelopmentKey launches and pipeline catalysts over the next 12 months should build confidence in GSK's £40B sales target by 2031, the majority of which is from on-market products.
Product DevelopmentThe launch of depemokimab is another inflection point given the opportunity biologics have to further penetrate the respiratory market.
Product LaunchesBlenrep's U.S. PDUFA and commercial launches will be key factors in achieving GSK's target.
Bears Say
External ChallengesDespite the uncertain external environment, GSK is confident in its ability to navigate challenges.
Sales Target ConcernsGSK noted the majority (50%+) of its 2031 sales target of £40B is from products already on the market.
GlaxoSmithKline News
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was $31.71 and its highest was $49.31 in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is $98.47B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Feb 04, 2026 which is in 51 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Oct 29, 2025. The company reported $1.457 earnings per share for the quarter, beating the consensus estimate of $1.257 by $0.2.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Overvalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of $0.41 which represents an annual dividend yield of 3.42%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 0.63.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 2,038,406,300 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of $1.457 in its last earnings report, beating expectations of $1.257. Following the earnings report the stock price went up 5.1%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GSK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GlaxoSmithKline Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$43.00 (-11.90% Downside)
$43.00 (-11.90% Downside)
Blogger Sentiment
Bullish
GSK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 360.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.92%
12-Months-Change
Fundamentals
Return on Equity
35.62%
Trailing 12-Months
Asset Growth
6.05%
Trailing 12-Months
Company Description
GlaxoSmithKline
GlaxoSmithKline (GSK) is a global healthcare company headquartered in the United Kingdom, specializing in pharmaceuticals, vaccines, and consumer healthcare products. With a diverse portfolio, GSK focuses on areas such as respiratory, oncology, immunology, and infectious diseases. The company is committed to research and development, aiming to deliver innovative treatments and preventive measures to improve patient health worldwide.
GSK Company Deck
GSK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted GSK's strong financial performance, significant growth in specialty medicines, and progress in R&D with FDA approvals. However, challenges remain in the U.S. vaccine market, delays in the HIV treatment study, and impacts from Medicare redesign and Zantac settlements.View all GSK earnings summariesGSK Stock 12 Month Forecast
Average Price Target
$43.00
▼(-11.90% Downside)
Technical Analysis
Ownership Overview
―
Insiders
6.62% Mutual Funds
10.49% Other Institutional Investors
82.61% Public Companies and Individual Investors